Submitted by Anonymous (not verified) on 20 November 2023 - 11:38
Human medicines European public assessment report (EPAR): Ajovy, fremanezumab, Migraine Disorders, Date of authorisation: 28/03/2019, Revision: 10, Status: Authorised
Source: